Abstract. Previous studies in hereditary and sporadic prostate cancer have indicated the existence of a tumor suppressor gene in chromosomal region 19p13. The BRG1 gene in this region is one of the possible candidates, based on both the frequency of inactivating mutations in human cancer cell lines, including the prostate cancer cell line DU145, and its functional properties. To our knowledge, no studies have been done to evaluate possible involvement of the BRG1 gene in clinical prostate cancer. To accomplish this, we carried out a complete mutation analysis of all 35 BRG1 exons in tumor and constitutional DNA samples from 21 prostate cancer patients. We report the absence of somatic mutations in the panel of samples employed, but the existence of five germline single nucleotide polymorphisms (SNPs) in CpG islands of the BRG1 gene, among them, three novel ones. In conclusion, the study excludes the presence of common BRG1 mutations in prostate cancer.
Introduction
Prostate cancer is a complex disease with multiple genetic and environmental factors involved (1) . It is characterized by heterogeneous growth and progression patterns ranging from silent harmless lesions detected only at autopsy to very rapidly growing and early metastasizing tumors. Potential precursor lesions can already be found at age 30, while clinically significant cancer is seldom found before the age of 50 years (2, 3) , suggesting the existence of factors that control progression from cancer initiation to onset of clinically significant manifestations.
From studies of familial and sporadic prostate cancer, several different chromosomal loci have been suggested to be involved in tumor development. Recently, a susceptibility locus has been assigned to chromosomal region 19p13 by a genome wide linkage screening in prostate cancer families (4) . Positive linkage to this region was mainly found in families with predominant accumulation of prostate cancer patients with early age of onset (4) . Alterations of chromosomal 19p region are also common in both hereditary and sporadic prostate cancer analyzed by comparative genomic hybridization (CGH) (5-7). Introduction of 19p can suppress the growth of transformed prostate epithelial cells in animal models (8) . These results suggest the existence of a tumor suppressor gene in 19p13.
One of the candidates in 19p13 is BRG1 (Brahma/SWI2 related gene-1) gene; also known as SMARCA4 (SWI/SNFrelated, Matrix-associated, actin-dependent, regulator of chromatin, subfamily A, member 4) gene. It contains 35 exons and encodes a component of the evolutionarily conserved SWI-SNF (switching or sucrose non-fermenting) chromatinremodeling complex, which provides ATPase activity necessary for transcriptional regulation at the level of nucleosome disruption (9) . The BRG1 protein has been implicated in cell growth and proliferation control through its interaction with the tumor suppressor RB1 (retinoblastoma 1) protein and may therefore participate in cell cycle regulation (10, 11) . This was further supported by findings that the SWI-SNF complex is associated with cyclin E in a BRG1-dependent manner (11) (12) (13) (14) . The latest data showed that RB and BRG1 co-operate to repress transcriptions of several E2F (adenovirus E2 promoter factor) target genes that are required for entry into S phase of the cell cycle (15) . Several BRG1 mutations have been found in human tumor cell lines, among them the prostate cancer cell line DU145. Most of these mutations result in a complete loss of the expression of normal BRG1 protein, suggesting that the BRG1 acts as a tumor suppressor (9) .
However, the involvement of the BRG1 gene in clinical cancer cases, including prostate cancer has not been evaluated. We therefore carried out a characterization of somatic mutations and constitutional genetic variants in all 35 exons of the BRG1 gene in a panel of 21 prostate cancer samples.
Patients and methods
Prostate cancer patients. In total, 21 prostate cancer patients were included in this study. All patients were ethnically of Swedish origin and had no familial history of prostate cancer.
They were all surgically treated at the Karolinska Hospital and the diagnosis was confirmed by histopathological examination. The Gleason grading and TNM staging systems were used to characterize tumor growth patterns and stage (16) (17) (18) . Table I . Primers used for PCR amplifications and sequencing of the BRG1 gene. 19R1 TTGTTCTGCAGCGGTGTGCC  165  19  19F2 GGCACACCGCTGCAGAACAA  19R2 ATGGGCACAGCTGGGCAAAC  153  20  20F GGAGGTAACGCTTGCTTC  20R TGAGGCTGCTTCACTGGT  192  21  21F GCATTATGTGTCCCCTGC  21R CAGTGGGGAATGCAGTTG  164  22  22F CCATTTGGGTCCCTCTCA  22R AGGAGCTCAGCAGACAGCA  169  23  23F TGCTCCTGCCTGTCACTGA  23R CCATCCAGTTGGGAAGCTTC  112  24  24F TCTCCTGCCTCCTCCACACT  24R CTCACCATCAAGCCTGAGG  196  25  25F TGCCCGTCAGGAACCACGAA  25R CCCGCTTTTACCTGGTGAGGA  185  26  26F1 TCCTGGGCTCCTTTGGGACT  26R1 CCTTCTGGTCCACGTTGAGCT  176  26  26F2 GAAGATCCTAGCTGCAGC  26R2 TCACCTCATCCTGCTCCT  142  27  27F TGACAGCCCTGGAGACTGA  27R GGAGACTGAACTACCCCTCT  166  28  28F CGGCACTGACAGTTTGCA  28R ATGCCTGAACTGCCCCAT  141  29  29F1 GTGCCTGCATGCTGATGCCT  29R1 TTCTCCTCCTCCTCCTCACAGG  187  29  29F2 CTGACCTGTGAGGAGGAGGA  29R2 GCCTCTCCAGCATGTACCTTG  119  30  30F1 CTGGGTGCTGGCTGTCCTAT  30R1 TGCTCTCGTCGTCCTTGTCG  184  30  30F2 CGACAAGGACGACGAGAGCA  30R2 CCTCCTCGCTTACCTGTCCTT  145  31  31F GTTCTGCCTTGCAGCAGCAGTGGAC  31R GCGCAGGTACAACGTCAGGGTTACC  147  32  32F GTAAGACCTGCTCCTCCCGT  32R AAAGCCCAGCTGTGGGAGT  182  33  33F AGTCGGGCCCATCCACTCAA  33R CCGGGACTCACATTCGGAT  185  34  34F GAGCTCAAGGCTGTCTTT  34R ACCTCCTCTTGTTCCTCCT  181  35  35F GCCAACGCACACTCTCTCCT  35R TCTCAGCTCTGGAACGAGGG  117 -
F, forward; R, reverse. Reference sequence: GeneBank AF20544908.
-
DNA analysis. High molecular tumor DNA was isolated from fresh frozen tumor tissues derived from 21 prostate cancer patients. The sampling procedure and representativity testing of the tumor samples have been described in detail in previous publications (19, 20) . Peripheral leukocytes obtained from the same patients were used as source of constitutional DNA. BRG1 mutation analysis was carried out in 21 pairs of matched tumor and constitutional DNA samples.
Single strand conformation polymorphism (SSCP).
All 35 coding exons of the BRG1 gene were screened for mutations by SSCP in 21 pairs of matched tumor and constitutional DNA samples from prostate cancer patients. The entire genomic BRG1 coding sequences together with all immediately adjacent intronic sequences, as well as 5' and 3' untranslated (UTR) sequences were amplified as 43 different fragments. The sizes of PCR fragments were approximately 100-200 bp to enable optimization of SSCP sensitivity. The largest exons (exon 2, 4, 6, 26, 29 and 30) were amplified as two or three PCR fragments, containing both intronic/exonic borders (Table I) . Primers for small exons were located at flanking intronic sequences. Forward primer for exon 1 and reverse primer for exon 35 were located at the 5' and 3' UTR respectively. Thus, the primer design allowed the detection of possible mutations located at coding as well as splicing regions.
All amplifications were carried out using Gold Taq polymerase (Applied Biosystems, CA). Each pair of primers (with a final concentration of 0.5 µM) was mixed with 50 ng of genomic DNA in a 20 µl standard PCR reaction and then subjected to initial denaturation at 95˚C for 6 min followed by 35 cycles of 94˚C for 30 sec, 60˚C for 30 sec, and 72˚C for 30 sec. The reaction was completed by a final extension at 72˚C for 7 min. Each PCR product was subjected to electrophoresis on 2% agarose gel containing 10% ethidium bromide. PCR bands were visualized under ultraviolet light.
The PCR products were used in cold SSCP analysis according to a procedure previously described (21) . We employed Novex 20% TBE (Tris-borate/ethylenediaminotetraacetic acid) non-denaturing polyacrylamide pre-cast gels (Invitrogen, CA) and a Novex ThermoFlow Mini-Cell chamber (Invitrogen, CA). Four µl of PCR product was mixed with 3 µl of stop solution containing 95% formamide, 5 mg bromophenol blue, 5 mg xylene cyanol, 20 mM EDTA at pH 8.0, and 9 µl milli-Q water to yield a 16 µl sample loading solution. After denaturation at 95˚C for 4 min, samples were run on a SSCP gel at 300 V constantly for 2.5-4 h (according to buffer temperature) in 1.25X TBE buffer. To reach higher sensitivity, each PCR fragment was analyzed at two different buffer temperature conditions (12˚C and 24˚C). After electrophoresis, gels were silver stained using the silver staining kit (Bio-Rad, CA) according to the recommended protocol. Each SSCP finding was verified by repeating both the PCR and SSCP for the given sample.
Direct DNA sequence analysis. Whenever a SSCP shift was detected, the corresponding PCR fragment was sequenced. Thermal cycling DNA sequencing was carried out using the BigDye kit (Applied Biosystems, CA) according to the protocol supplied by the manufacturer. Briefly, after purification by a Micro Bio-Spin column (Bio-Rad, CA), 40 ng of PCR product was mixed with 3.2 pmol sequencing primer and 2.5 µl BigDye to a final volume of 20 µl. The reaction mix was then subjected to 25 cycles of thermal cycling at 96˚C for 10 sec, 50˚C for 5 sec and 60˚C for 4 min. The sequencing reactions were fractionated in an ABI PRISM 310 Genetic Table II . Single nucleotide polymorphisms (SNPs) of the BRG1 gene detected in prostate cancer patients. 
-----------------------------------------------------------------------------------------------------

Nucleotide position is according to the reference GeneBank sequence: AF20544908. dbSNP (http://www.ncbi.nlm.nih.gov/SNP).
Sequence Analyzer (Applied Biosystems, CA). Each PCR fragment has been sequenced and analyzed in both forward and reverse directions.
Results
In total, distinct band shifts were found by SSCP in five different PCR fragments (Table II) . For all cases, the band shifts were observed in both constitutional and tumor DNA samples, indicating the presence of germline sequence variants (Fig. 1) . Sequence results showed that each of these band shifts was caused by a single nucleotide substitution at a CpG island, one in intron 22 and four in coding sequences of exons 9, 29, 32, and 34. As none of these sequence variants was predicted to cause alterations of the encoded amino acids, they were regarded as single nucleotide polymorphisms (SNPs). Two (SNP33978 and SNP64585) of the five SNPs detected have been reported (http://www.ncbi.nih.gov/SNP/), while three (SNP74061, SNP97884 and SNP99209) were novel. The frequencies by which the alternative genotypes were detected in prostate cancer patients are summarized in Table II . Additionally, we compared the frequency of SNP genotypes with the age at diagnosis and histological grade (Gleason score) . Results are summarized in Table III .
Although the sample size in this study is not large enough to perform any significant allelic association analysis, some tendencies in correlation can still be observed, e.g. the data from Table III suggest that patients with T/T genotype at SNP33978 or with C/C genotype at SNP64585 were diagnosed earlier and had higher Gleason score in comparison with those having other genotypes at the corresponding SNPs.
Discussion
In this study we aimed to evaluate the possible involvement of BRG1 in clinical prostate cancer development. The lack of BRG1 somatic mutations in our set of prostate tumor samples 
is very unlikely to be a false negative result, since this panel of tumor DNA samples has previously been used for the typing of over 30 microsatellite markers in loss of heterozygosity (LOH) studies on 13q and 16q (19, 20) . Clear LOH has been found in over 50% of the samples analyzed, confirming the high tumor cell content of the tumor tissue samples used for DNA extraction. The SSCP analysis, which was carried out at two different temperature conditions, enabled detection of five frequent polymorphisms in different parts of the BRG1 gene. Direct DNA sequencing revealed that these polymorphisms represent different single nucleotide substitutions, supporting the optimization of the SSCP method in our study.
The absence of somatic mutations in the panel of samples employed does not support the assumption of the BRG1 gene being a typical tumor suppressor gene in prostate cancer. However, taking into account that the searching for new SNPs in cancer-associated genes is one of the latest approaches in connection with the human genome sequence project and the cancer genome anatomy project (22) , and that some SNPs even without differences in the encoded amino acids have been applied in precise disease gene mapping as well as associated with clinical and prognostic parameters (23, 24) , the potential allelic associations of BRG1 SNPs with the clinical features of prostate cancer could be of interest for further analyses in a larger number of samples.
